Literature DB >> 21668504

Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma.

Ann Kristin Kvam1, Peter M Fayers, Finn Wisloff.   

Abstract

OBJECTIVES: The aims of this study were to (i) compare the responsiveness of the EORTC QLQ-C30 cancer-specific questionnaire and the generic questionnaires EQ-5D and 15D used for economic evaluation of healthcare interventions and (ii) determine the minimal important differences (MIDs) in these questionnaires. The MID is the smallest change in a quality-of-life score considered important to patients.
METHODS: Between 2006 and 2008, 239 patients with multiple myeloma completed the questionnaires at inclusion (T1) and after 3 months (T2). At T2, patients were asked whether they had noticed any change in their quality of life. Responsiveness and MIDs were determined by mean score changes (T2-T1) for patients who, in the interview, stated they had improved, deteriorated, or were unchanged. Responsiveness was also assessed using standardized response means. Wilcoxon tests for pair differences were used to evaluate the statistical significance of the changes.
RESULTS: Patients who improved had significantly (P < 0.01) higher scores at T2 in all three questionnaires. Patients who deteriorated reported lower scores at T2; however, for the 15D, the differences in score were not statistically significant. The MIDs for the QLQ-C30, EQ-5D, and 15D were 8, 0.08, and 0.03 in patients who improved and 12, 0.10 and 0.02 in patients who deteriorated, respectively.
CONCLUSIONS: All three questionnaires showed an acceptable responsiveness in patients who improved. However, the 15D did not respond optimally in patients who deteriorate and cannot be recommended for use in patients with myeloma.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2011        PMID: 21668504     DOI: 10.1111/j.1600-0609.2011.01665.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  31 in total

Review 1.  Can The EQ-5D Detect Meaningful Change? A Systematic Review.

Authors:  Nalin Payakachat; Mir M Ali; J Mick Tilford
Journal:  Pharmacoeconomics       Date:  2015-11       Impact factor: 4.981

2.  Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma.

Authors:  Kevin W Song; Meletios A Dimopoulos; Katja C Weisel; Philippe Moreau; Antonio Palumbo; Andrew Belch; Stephen Schey; Pieter Sonneveld; Lars Sternas; Xin Yu; Ramesh Amatya; Mara S Monzini; Mohamed Zaki; Christian Jacques; Jesus San Miguel
Journal:  Haematologica       Date:  2014-11-25       Impact factor: 9.941

3.  EQ-5D-derived health utilities and minimally important differences for chronic health conditions: 2011 Commonwealth Fund Survey of Sicker Adults in Canada.

Authors:  Kate Tsiplova; Eleanor Pullenayegum; Tim Cooke; Feng Xie
Journal:  Qual Life Res       Date:  2016-06-15       Impact factor: 4.147

4.  Quality of life assessed with EQ-5D in patients undergoing glioma surgery: what is the responsiveness and minimal clinically important difference?

Authors:  Lisa Millgård Sagberg; Asgeir S Jakola; Ole Solheim
Journal:  Qual Life Res       Date:  2013-12-07       Impact factor: 4.147

5.  Health state utility and quality of life measures in patients with chronic myeloid leukemia in France.

Authors:  Foulon S; Cony-Makhoul P; Guerci-Bresler A; Daban M; Kapso R; Tubert-Bitter P; Bonastre J
Journal:  Qual Life Res       Date:  2021-03-02       Impact factor: 4.147

6.  Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.

Authors:  Michel Delforge; Leonard Minuk; Jean-Claude Eisenmann; Bertrand Arnulf; Letizia Canepa; Alberto Fragasso; Serge Leyvraz; Christian Langer; Yousef Ezaydi; Dan T Vogl; Pilar Giraldo-Castellano; Sung-Soo Yoon; Charles Zarnitsky; Martine Escoffre-Barbe; Bernard Lemieux; Kevin Song; Nizar Jacques Bahlis; Shien Guo; Mara Silva Monzini; Annette Ervin-Haynes; Vanessa Houck; Thierry Facon
Journal:  Haematologica       Date:  2015-03-13       Impact factor: 9.941

7.  Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.

Authors:  A Keith Stewart; Meletios A Dimopoulos; Tamás Masszi; Ivan Špička; Albert Oriol; Roman Hájek; Laura Rosiñol; David S Siegel; Ruben Niesvizky; Andrzej J Jakubowiak; Jesus F San-Miguel; Heinz Ludwig; Jacqui Buchanan; Kim Cocks; Xinqun Yang; Biao Xing; Naseem Zojwalla; Margaret Tonda; Philippe Moreau; Antonio Palumbo
Journal:  J Clin Oncol       Date:  2016-11-10       Impact factor: 44.544

8.  The influence of surgery on quality of life in patients with intracranial meningiomas: a prospective study.

Authors:  Asgeir S Jakola; Michel Gulati; Sasha Gulati; Ole Solheim
Journal:  J Neurooncol       Date:  2012-07-27       Impact factor: 4.130

9.  Quality of life following concurrent temozolomide-based chemoradiation therapy or observation in low-grade glioma.

Authors:  Deborah Y Park; Martin C Tom; Wei Wei; Surabhi Tewari; Manmeet S Ahluwalia; Jennifer S Yu; Samuel T Chao; John H Suh; David Peereboom; Glen H J Stevens; Gene H Barnett; Lilyana Angelov; Alireza M Mohammadi; Thomas Hogan; Courtney Kissel; Brittany Lapin; Isabel Schuermeyer; Michael W Parsons; Richard Naugle; Erin S Murphy
Journal:  J Neurooncol       Date:  2022-01-22       Impact factor: 4.130

10.  Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial.

Authors:  Stefan Knop; Maria-Victoria Mateos; Meletios A Dimopoulos; Kenshi Suzuki; Andrzej Jakubowiak; Chantal Doyen; Paulo Lucio; Zsolt Nagy; Ganna Usenko; Ludek Pour; Mark Cook; Sebastian Grosicki; Andre Crepaldi; Anna Marina Liberati; Philip Campbell; Tatiana Shelekhova; Sung-Soo Yoon; Genadi Losava; Tomoaki Fujisaki; Mamta Garg; Jianping Wang; Susan Wroblewski; Anupa Kudva; Katharine S Gries; John Fastenau; Jesus San-Miguel; Michele Cavo
Journal:  BMC Cancer       Date:  2021-06-02       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.